Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: D.Lu who wrote (11090)	3/30/2017 11:07:23 AM
From: Biotech Jim	Read Replies (1) \| Respond to of 12215

CARA had registered a shelf offering on March 13 this year. It was for $250M. So this offering is for 1/3 of the shelf. If I was in charge, I would have had the lead underwriters be a bit more aggressive in this share follow on offering. This was Stiefel and Piper Jaffray. The time to raise more money at a biotech is when you do not need it, and the share price is high. So I would expect or want CARA to raise more money after the (hopefully) positive OA oral CR845 trial data comes out. They soon will have 3 Ph3 trials ongoing. If the stock closes above $20 or so, look out above. That would be quite bullish.